October 2 – 4 2023 | Boston, MA

Unlocking the Full Potential of Bi, Tri- & Multispecfic Antibody Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize Therapeutic Windows

Be at the forefront of the Bispecific space as it goes head-to-head with cell therapy to transform oncology. Among numerous innovations in cancer immunotherapy, Bispecific antibody treatments have never been more promising with continuous clinical updates and approvals over the last year, including the huge waves seen in multiple myeloma and lymphoma treatment.

The World Bispecific Summit returns for its 14th year with an enriched program boasting comprehensive coverage of all the key discovery, pre-clinical, and clinical challenges including design, clinical, regulatory, and combination strategies. Led by the industry’s brightest minds from the likes of Sanofi, Regeneron, the FDA, Alligator Biosciences, and Amgen, it’s the perfect platform to celebrate wins, work through challenges, and establish connections with the leading pharma, biotech, and academic KOLs.

Access your copy of the full event guide with 35+ world-class speakers. Beacon’s Bispecific expert, Flavio Lima Bianchi, will be joining this leading speaker faculty and opening the conference with a review of the landscape, covering the past, present, and future of biologics.

Deep dive into novel target selection, immune cell modulators, target selection and pre-clinical/clinical readouts and gain holistic insight on the current state-of-play in the bispecific landscape to supercharge your own pipeline from discovery through to IND approval.

To join our longstanding Bispecific community in Boston, register your place here.